心可舒片干预非ST段抬高型急性冠脉综合征PCI患者临床观察

Clinical observation of Xinkeshu Tablet in PCI Patients with NSTEACS

目的:探讨心可舒片对非ST段抬高型急性冠脉综合征PCI患者的治疗效果。方法:选择安徽中医药大学第一附属医院2020年12月—2021年6月住院患者,诊断为非ST段抬高型急性冠脉综合征并于医院行PCI术治疗的患者60例。随机分为对照组和治疗组。比较两组间治疗前后的心绞痛分级、肌钙蛋白(cTnI)、心电图疗效、血清N末端B型脑钠肽前体(NT-proBNP)、TIMI血流分级及CTFC帧数疗效、MACE事件发生率。结果:治疗组在非ST段抬高型急性冠脉综合征PCI患者的心绞痛分级、肌钙蛋白(cTnI)、心电图疗效、血清N末端B型脑钠肽前体(NTproBNP)、TIMI血流分级及CTFC帧数疗效方面,相比于对照组更好,差异具有统计学意义(P<0.05)。结论:心可舒片治疗非ST段抬高型急性冠脉综合征PCI患者的临床疗效确切,能够明显改善患者的心绞痛症状。

Objective: To explore the therapeutic effect of Xinkeshu Tablets on patients with non-ST-segment elevation acute coronary syndrome undergoing PCI. Methods: Selected 60 inpatients in the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine from December 2020 to June 2021 who were diagnosed with non-ST-segment elevation acute coronary syndrome and underwent PCI in the hospital. Randomly divided into control group and treatment group. The grade of angina pectoris, troponin(cTnI), curative effect of electrocardiogram, serum N-terminal pro-B-type natriuretic peptide(NT-proBNP), TIMI blood flow grade, curative effect of CTFC frame number, and incidence of MACE events were compared between the two groups before and after treatment. Results: The angina pectoris grade, troponin(cTnI), electrocardiogram curative effect, serum N-terminal B-type natriuretic peptide precursor(NT proBNP), TIMI blood In terms of flow classification and CTFC frame number, it was better than the control group, and the difference was statistically significant(P<0.05). Conclusion: Xinkeshu Tablets has a definite clinical curative effect in the treatment of PCI patients with non-ST-segment elevation acute coronary syndrome, and can significantly improve the symptoms of angina pectoris in patients.